Cite
HARVARD Citation
Jebali, M. et al. (2017). Biological toxicities as surrogate markers of efficacy in patients treated with mTOR inhibitors for metastatic renal cell carcinoma. BMC cancer. 17 (1), pp. 1-7. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Jebali, M. et al. (2017). Biological toxicities as surrogate markers of efficacy in patients treated with mTOR inhibitors for metastatic renal cell carcinoma. BMC cancer. 17 (1), pp. 1-7. [Online].